GSK and Novartis announce collaboration to support scientific research into genetic diversity in Africa
For media and investors only
Issued: London UK
- Project Africa GRADIENT calls on local researchers to submit proposals exploring the link between genetic diversity and response to malaria and tuberculosis drugs in African patients.
- Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years.
- Researchers based at universities, science councils and other public research organisations across Africa are invited to express ‘intent to submit’ by March 1, 2021.
GSK and Novartis today announced the launch of a collaboration to support high-quality scientific research investigating the link between genetic diversity across different regions in Africa and its potential impact on response to drug therapeutics.
The Project Africa Genomic Research Approach for Diversity and Optimising Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8m (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis.[1]
Pauline Williams, Senior Vice President Global Health Pharma at GSK said: “At GSK, human genetics is a core pillar of our R&D strategy. Genetic diversity is greater in Africa than in any other continental population resulting in some African patients having varying response to treatments. We are excited to launch Project Africa GRADIENT which aims to catalyse the best science in the continent to optimise treatment responses for malaria and tuberculosis, two infectious diseases that disproportionately affect African populations.”
Lutz Hegemann, M.D., Chief Operating Officer for Global Health at Novartis said: “Novartis has a long-standing commitment to improving and extending the lives of patients around the world. Our efforts include seeking innovative ways to improve the standard of care where possible. This is why we are excited by this important collaboration on scientific research on genetic diversity in Africa. It has the potential to improve the efficacy and tolerability of current and future medicines, starting with two of the most deadly diseases, malaria and tuberculosis. In alignment with our ongoing efforts to strengthen scientific capabilities in lower-resource settings, this project also provides opportunities for training young African scientists in the use of advanced research methodologies and mentoring on drug development.”
Project Africa GRADIENT comprises three funding mechanisms to support:
- Fellowships: A limited number of fellowships in academic institutions with a reputation for global excellence to collect and analyse data on determinants of drug response.
- Investigator-sponsored research: Hypothesis-driven research focused on understanding genetic regional variation in drug response.
- Seed-Fund: A limited number of projects to enable the exploration of new research goals, depending on the results from 1 and 2.
Within the scope of the agreement, the South African Medical Research Council (SAMRC) will administer the project, and a Joint Steering Committee will oversee the review of submitted proposals. Priority will be given to research aimed at collecting data from currently under-represented regions and improving the scientific robustness of inconsistent data. All datasets collated are planned to be released in a public database to catalyse a positive change in approach to understanding variations in treatment efficacy and safety for patients across the continent.
Prof. Glenda Gray, SAMRC President and CEO, said: “It is exciting to see more and more global partners taking interest in the challenges of Africa. We are delighted that partners are now seeking to address the challenges of Africa by their quest to understand the fundamental differences between genetics of Africa and the rest of the world.”
As a first step, researchers based at universities, science councils and other public research organisations across Africa are invited to express their ‘intent to submit’ through the SAMRC website https://www.samrc.ac.za/request-for-applications/project-africa-gradient. Final award recipients are expected to be announced by end of 2021.
About Project Africa GRADIENT
GSK is committed to improve global health impact through R&D for infectious diseases that affect children and adolescents in the developing world, with a particular but not exclusive, focus on malaria, TB and HIV/AIDS. Novartis is reimagining medicine to improve and extend people’s lives. The Novartis Global Health & Corporate Responsibility organisation drives global efforts in the elimination or control of four flagship diseases: malaria, leprosy, sickle cell disease and Chagas disease.
In 2018, GSK and Novartis entered into an agreement to fund projects to explore genetic variation across Africa with a potential to influence drug response, which may lead to differences in drug efficacy and safety. Both parties are jointly funding the Project Africa Genomic Research Approach for Diversity and Optimising Therapeutics (GRADIENT), which will commence with key infectious diseases affecting African populations (i.e. tuberculosis and malaria) with the possibility to expand to other diseases in the future. In 2019, GSK and Novartis appointed the South Africa Medical Research Council as the administrator of the project.
Project Africa GRADIENT builds on GSK’s Africa NCD (non-communicable diseases) Open Lab facilitating research in Africa and contributing to building research excellence and networks across Sub-Saharan African scientists, and follows research supported by the Novartis Institutes for BioMedical Research on African genetic diversity.[2]
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.
For more information visit www.novartis.com or contact media.relations@novartis.com.
References
[1] Rajman I, Della Pasqua O. Introducing Project Africa GRADIENT, Drug Discov Today (2019 ),24, 2229-30. https://doi.org/10.1016/j.drudis.2019.10.010
[2] Rajman I, Knapp L, Morgan T, Masimirembwa C. African genetic diversity: Implications for cytochrome P450-mediated drug metabolism and drug development. Ebiomedicine (2017) 17: 67-74. https://doi.org/10.1016/j.ebiom.2017.02.017
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2019.
